Vomiting

06/01/2010 - "The GA group received a significantly greater number of antiemetic doses intraoperatively (0.58 vs 0.04, P < .001) but still had a higher, although nonsignificant, rate of emesis (15.5% vs 10.0%). "
07/01/1988 - "Furthermore, the antiemetic efficacy of MCP plus DPH (0-2 vomiting episodes: 45%) was significantly enhanced (p less than 0.05) by the combined use of MPL plus DZP (0-2 vomiting episodes: 76%)."
01/01/2000 - "Because vomiting can compromise the efficacy of ECPs, routine pretreatment with an antiemetic is recommended. "
02/01/2017 - "Adherence to antiemetic guidelines effectively controls vomiting but is less effective against delayed CINV in both HEC and MEC patients. "
05/01/2003 - "The management of acute-onset emesis (< 24 hours post-treatment) has improved markedly in recent years and the 5-HT3-receptor antagonists are widely regarded as the antiemetic 'gold standard' during this period. "

10/01/2017 - "Ondansetron has proven to be a safe and effective adjunct in children with vomiting. "
01/01/1999 - "However, there was a significant reduction in emesis management costs for patients treated after versus before the availability of ondansetron: for patients treated in the last third versus first third of the study period, there was a decrease in cost per patient per month of treatment of $374 (95% confidence interval, $243 to $505). "
11/01/2012 - "In conclusion, the administration of oral ondansetron to children with vomiting in the emergency department is clinically effective and results in significant economic savings."
12/01/2001 - "The incidence of vomiting was significantly greater after infusion of placebo than after either low-dose or high-dose ondansetron. "
12/01/1997 - "All doses of ondansetron 0.05 mg/kg, 0.1 mg/kg, and 0.15 mg/kg were significantly more effective than placebo in reducing the incidence of emesis prior to, following discharge, and during the first 24 postoperative hours (p < 0.001). "

04/01/2008 - "A significant reduction in vomiting from 27% to 11% was achieved following the introduction of routine use of intravenous dexamethasone during surgery. "
04/01/2003 - "Compared with placebo, dexamethasone significantly decreased the incidence of early and late vomiting (P < 0.05, P < 0.001 respectively). "
02/01/1995 - "Addition of dexamethasone significantly improved prevention of both acute and delayed emesis. "
01/01/1998 - "Six patients in group D and 19 in group S experienced vomiting at least once within the 24-h postoperative period; dexamethasone was effective in reducing the overall incidence of vomiting from 63.3% to 20.0% (P < 0.01). "
10/01/2000 - "Dexamethasone is clearly effective in protecting from emesis both in the acute and delayed phases, with emesis avoided in one patient out of six treated. "

02/01/2000 - "All three agents were highly effective against cisplatin-induced acute and late vomiting and the results were statistically significant. "
01/01/1992 - "Most patients (64%) experienced emesis if C[4h] was < 20 ng/ml, whereas emesis did not occur in any patient with C[4h] > 80 ng/ml. Among patients receiving very high dosages of cisplatin (> 95 mg/m2), comparable levels of systemic exposure were not totally effective in preventing emesis. "
07/01/1988 - "These results indicate that high-dose MCP plus DPH are effective in preventing cisplatin-induced vomiting. "
11/01/1987 - "M+L significantly reduced severity of vomiting (P = 0.005) and number of vomiting episodes (P = 0.03) in the cisplatin subset. "
05/01/1983 - "Of considerable importance is the recent evidence of its efficacy when administered intravenously in high dosages in preventing severe vomiting associated with cisplatin. "

11/01/1989 - "There was a significant reduction in the number of episodes of vomiting during the first 24 h in patients receiving the metoclopramide combination (P = 0.0001). "
11/01/1984 - "Pharmacokinetics and efficacy of high-dose metoclopramide given by continuous infusion for the control of cytotoxic drug-induced vomiting."
08/01/2011 - "All three studies were included in the final meta-analysis that demonstrated an overall result of no difference between metoclopramide and placebo for the primary outcome of vomiting (odds ratios 0.72; 95% confidence intervals 0.11-4.58). "
12/01/1995 - "At this time, the reference treatment for emesis was metoclopramide and thus, phase III trials have been initially conducted with this comparative treatment. "
03/01/1986 - "[Randomized controlled study of high-dose metoclopramide (2 mg/kg x 4:H) vs moderate-dose metoclopramide (1 mg/kg x 4:M) in the prevention of CDDP-induced emesis]."

08/01/2012 - "The efficacy of granisetron was measured on each day using the complete regression(no vomiting and no rescue medication; CR)rate. "
09/01/1997 - "The percentage of emesis-free patients was significantly greater in the 5- to 20-microg/kg granisetron groups than in the control and 2-microg/kg granisetron groups (18%, 23%, 68%, 78%, and 75% of patients receiving saline or granisetron 2 microg/kg, 5 microg/kg, 10 microg/kg, and 20 microg/kg, respectively). "
08/01/2003 - "Additionally, incremental doses of granisetron (up to 9 mg) have been shown to be effective and well tolerated in patients with refractory emesis. "
02/02/2016 - "Three studies compared granisetron 20 mcg/kg with 40 mcg/kg for complete control of vomiting (pooled RR 0.93; 95% CI 0.80 to 1.07). "
05/01/2013 - "Granisetron reduces post-operative vomiting in children: a dose-ranging study."

07/01/2011 - "Vomiting was dramatically reduced by the concomitant administration of aprepitant. "
06/01/2011 - "Aprepitant markedly improved control of emesis in patients with one or more risk factors. "
04/01/2010 - "The aprepitant regimen provided superior efficacy in the treatment of CINV in a broad range of patients receiving MEC (non-AC or AC) in both no vomiting and complete response endpoints. "
12/01/2013 - "To investigate efficacy of aprepitant in children and young adolescents with high or moderate emetogenic courses, with uncontrollable emesis in previous cycles. "
12/01/2013 - "Aprepitant might be effective in preventing or reducing vomiting in children. "

03/13/2023 - "There was a significant improvement in the scores of Functional Living Index-Emesis in patients using palonosetron."
07/01/2014 - "In conclusion, palonosetron and first-generation 5-HT3 RAs were at least equally effective in emesis prophylaxis for allo-HSCT recipients. "
01/01/2018 - "The efficacy of palonosetron in preventing emesis was evaluated in 40 patients. "
08/01/2014 - "However, palonosetron has also shown consistent improvement in the suppression of delayed emesis. "
03/13/2023 - "The incidence of complete response and proportion of patients with higher Functional Living Index-Emesis scores were significantly higher in patients using palonosetron. "

08/01/2014 - "Acute emesis has largely been alleviated with the use of 5-HT3 receptor antagonists, while an improvement in preventing delayed emesis has been achieved with NK1 receptor antagonists. "
07/01/2000 - "Studies have yielded conflicting results concerning the use of 5-HT3 receptor antagonists alone in delayed emesis. "
06/01/1996 - "Further studies in animals have provided valuable information relating to the pathophysiology of emesis and the mechanism of action of 5-HT3 receptor antagonists. "
01/01/2017 - "At present, it is not possible to suggest a specific 5-HT3 receptor antagonist to use for the prevention of acute emesis in these patients. "
06/01/2011 - "The most well established physiological roles of the 5-HT3 receptor are to coordinate emesis and regulate gastrointestinal motility. "

04/01/1996 - "Furthermore, based on our improved knowledge of the role of 5-HT in emesis and gastrointestinal motility, the therapeutic potential of potent mixed 5-HT4 agonists--5-HT3 antagonists in the control of cytotoxic-drug-induced emesis and associated gut motor disturbances will be discussed. "
02/01/2003 - "The introduction of serotonin 5-HT(3)-receptor antagonists into clinical practice allowed for a dramatic improvement in the management of vomiting. "
11/14/2014 - "This study was the first to determine the relationship between 5-HT and emesis-induced motor activity."
12/01/2006 - "Laboratory studies provide additional evidence that serotonin and SP are involved primarily, though not exclusively, in acute and delayed vomiting, respectively."
01/01/2003 - "In an attempt to examine the background of SSRI-induced emesis, the present study aims to describe the role of 5-hydroxytryptamine (serotonin:5-HT) from the viewpoint of 5-HT release in the mouse-isolated ileum. "

11/01/1995 - "The combination of PNC + DXM is more efficacious than PNC + PLC in protection against highly emetogenic chemotherapy-induced vomiting."
11/01/1993 - "In fact, 70-80% of patients submitted to highly or moderately emetogenic drugs achieve complete protection against vomiting during the first cycle of chemotherapy. "
07/01/1996 - "This drug is a good protective against chemotherapy induce emesis and is very easy to administer."
06/01/2004 - "Simple diffusion of guidelines was evaluated in an observational study in the 77 new centers, while the double combination of simple diffusion and "audit and feedback" strategy was randomly compared in the old centers with the triple combination of the same two strategies plus an "educational outreach visit." Simple diffusion of guidelines improved the prescription but only for acute and delayed emesis induced by high-moderate emetogenic chemotherapy. "
11/01/2021 - "The chemotherapy-induced vomiting (CIV) severely affects the daily function, nutritional status, treatment compliance, therapeutic efficacy, curability, and the quality of life of patients. "

07/01/2023 - "ternata-containing TCM combined with 5-HT3RAs significantly improved the CER of CINV (RR = 1.46, 95% CI = 1.37-1.57, p < 0.00001), appetite (RR = 1.77, 95% CI = 1.42-2.20, p < 0.00001), QOL (RR = 7.67, 95% CI = 1.56-13.78, p = 0.01), the CER of several 5-HT3RA medications (RR = 1.47, 95% CI = 1.37-1.57, p < 0.00001), and acute and delayed vomiting (RR = 1.23, 95% CI = 1.12-1.36, p < 0.0001) compared with the 5-HT3RAs alone, while the combination therapy decreased the incidence of side effects induced by 5-HT3RAs for CINV (RR = 0.50, 95% CI = 0.42-0.59, p < 0.00001). "
08/01/2014 - "In infants with symptoms attributed to GER, LLP produced a significant reduction in total GER, but did not result in a significant improvement in symptoms other than vomiting; however, automated analysis appeared to identify infants with GER-associated crying symptoms who responded to positioning therapy. "
01/01/2023 - "Ear Plaster Therapy as a Safe and Effective Treatment for Gestational Vomiting."
12/01/2019 - "After 5 weeks following the surgery, which were uneventful, the patient was repeatedly hospitalized in the surgical department for extreme vomiting; however, her health status rapidly improved with infusion therapy followed by careful re-alimentation. "
05/21/1990 - "[Assessment of the efficacy of drugs used in prevention of vomiting during anticancer therapy in children]."

07/01/2006 - "Acupressure (two trials) and acupuncture (six trials) modalities were effective in reducing vomiting (P < .005); however, ETS (two trials) did not show significant effects in reducing the vomiting (P = .118) in children. "
08/01/2021 - "The acupressure effect on vomiting incidence didn't differ in both males and males, whilst ginger helped the males more."
07/01/2004 - "This study suggests that acupressure on P6 point appears to be an effective adjunct maneuver in the course of emesis control."
05/01/2006 - "Korean hand acupressure stimulations (two trials) had the best impact on reducing vomiting. "
10/01/2022 - "We used four tools for data collection: (1) a structured questionnaire comprising two parts: (a) characteristics of nurses and children and (b) assessment of nurses' knowledge; (2) an observational checklist for application of acupressure technique; (3) the Baxter Animated Retching Faces (BARF) scale; and (4) a vomiting assessment sheet. "

12/01/2021 - "It carries likely benefits in the form of analgesia, anti-emesis and improved appetite in chronic patients. "
08/05/2021 - "She had been vomiting for the last 24 hours and her mother's primary reason for presentation was that she was unable to keep down any analgesia . "
05/01/2020 - "General anaesthesia followed together with multi-modal analgesia and anti-emesis. "
01/28/2019 - "Mean duration of analgesia in group A was 264.12 ± 68.77 minutes and in group B was 520 ± 57.37 minutes, p-value <0.001.Incidence of vomiting was 9% in group A compared to 6% in group B. "
01/01/2018 - "Analysis of a large prospective cohort study failed to find evidence of an association between emesis and shortened fasting time upon implementation of a shortened fasting protocol for procedural sedation and analgesia."

01/01/2010 - "A prospective observational trial on emesis in radiotherapy: analysis of 1020 patients recruited in 45 Italian radiation oncology centres."
11/01/1998 - "International study results concerning radiotherapy-induced emesis are demonstrated. "
01/01/2021 - "Radiation-induced emesis (RIE) is usually noted during abdominal-pelvic radiotherapy. "
10/01/2018 - "Radiation therapy and delayed emesis."
05/01/2012 - "The patients documented emesis daily during the radiotherapy period. "